Journal of Current Ophthalmology最新文献

Purpose: To investigate ophthalmic manifestations in coronavirus disease 2019 (COVID-19) patients admitted to a designated COVID-19 center in Northern India during the period from April 13, 2020, to April 13, 2022. This aims to provide a comprehensive understanding of ocular involvement in the context of the pandemic.

Methods: This is a hospital-based prospective observational study. All COVID-19-positive (reverse transcriptase polymerase chain reaction positive - via pharyngeal and nasal swabs) patients, who were admitted to our hospital, were included in the study. Upon receiving ophthalmology referrals, patients were seen in the COVID-19 ward, with data collected on demographic distribution, presenting ocular symptoms, and specific ocular findings.

Results: Out of 3278 patients admitted to our center, 287 developed ocular symptoms. The study revealed a mean age of 63.8 ± 13.9 years, with males constituting 61.3% of the cases. The mean logMAR best-corrected visual acuity was found to be 0.30 ± 0.60. The mean duration between COVID-19 diagnosis and development of the first ophthalmic symptom was 10.4 ± 9.8 days. The predominant ocular symptoms included redness, discharge, and watering. Anterior segment manifestations were predominant, with conjunctivitis being the most prevalent ocular pathology (74.21%), followed by episcleritis (9.41%) and subconjunctival hemorrhage (7.31%). Conjunctivitis presented bilaterally in 41.5% of these patients, emphasizing its significance in the spectrum of COVID-19 ocular manifestations.

Conclusions: This research contributes substantial evidence regarding ophthalmic manifestations in COVID-19 patients. Ophthalmologists should remain vigilant, considering the potential for ocular symptoms to precede respiratory manifestations. The study emphasizes the need for comprehensive patient assessments and preventive measures in ophthalmic practices.

Purpose: To compare meibomian gland (MG) loss and MG dysfunction (MGD) in patients with mild versus moderate-severe thyroid eye disease (TED).

Methods: Consecutive patients with TED and no other causes of dry eye disease underwent meibography and meiboscore of each eyelid were graded as 0 (no MG loss), 1 (<33% loss), 2 (33%-66% loss), and 3 (>66% loss), with a total score of 0-6. MG expression score (0-3), eyelid margin signs of MGD, lipid layer thickness (LLT), ocular surface disease index (OSDI), tear secretion, noninvasive tear break-up time (NITBUT), and tear meniscus height (TMH) were also assessed by a masked observer.

Results: Included were 21 eyes (21 patients) with mild and 19 eyes (19 patients) with moderate-severe TED. The two groups were not different except for a higher frequency of smoking (P < 0.01). Eyes with moderate-severe TED showed a higher upper eyelid meiboscore (P = 0.03), MG expression score (P < 0.01), and tear film osmolality (P = 0.02) as well as lower LLT (P = 0.03). Total meiboscore had a significantly positive correlation with OSDI (r_s = 0.37) and tear film osmolality (r_s = 0.50) as well as a negative correlation with NITBUT (r_s = -0.55), TMH (r_s = -0.44), and LLT (r_s = -0.38). While older age, male gender, smoking, and longer duration of disease were significantly associated with the higher (≥3) meiboscore in univariate analysis, none remained significant in multivariate analysis.

Conclusion: MG loss and MGD were significantly more severe in moderate-severe than mild TED.

Purpose: To do a qualitative and quantitative assessment of the existing literature on the effectiveness and safety of pilocarpine 1.25% eye drops in presbyopia management.

Methods: Relevant articles were extracted from the online database using keywords - "pilocarpine and presbyopia", "AGN-190584 and presbyopia", and "Vuity and presbyopia". The primary outcome measure considered was an improvement in distance-corrected near visual acuity (DCNVA) and secondary outcome measures were improvement in distance-corrected intermediate visual acuity (DCIVA) and adverse events (AEs). Risk of bias (ROB) assessment was done using the ROB2 tool and R software was used for quantitative analysis.

Results: The 3 included randomized control trials (RCTs) had a total of 980 participants between 40-55 years of age. They were randomized into 2 groups - 489 in the pilocarpine group and 491 in the vehicle group. In the pilocarpine group, 1.25% of pilocarpine was used either once (in the Gemini 1 and 2 trials) or twice daily (Virgo trial). A significantly higher proportion of patients reported improvement of DCIVA and gain of ≥ 3 lines in binocular DCNVA in the pilocarpine group than the vehicle group (P < 0.01). Headache was the most commonly reported AE (13.49% of participants). Three case reports published on pilocarpine use for presbyopia management have reported vitreomacular traction in 1 and retinal detachment in 5 eyes.

Conclusions: The available evidence documents significant improvement in near and intermediate vision in presbyopia participants with pilocarpine 1.25% drop. However, more RCTs, involving a wider age group, larger refractive error, longer follow-up, and clinical testing in a real-world scenario are required to conclusively prove its role in presbyopia management.

Purpose: To report the atypical case of a patient with mucopolysaccharidosis type II (MPS II) in whom bilateral pigmented paravenous chorioretinal atrophy (PPRCA) was found.

Methods: An observational case report.

Results: We present the case of a 31-year-old male patient who presented with decreased visual acuity and in whom fundus examination and multimodal imaging revealed a typical appearance of bilateral symmetrical PPRCA. Our patient also had thick facies with hypertelorism and stubby hands, which prompted an enzyme assay revealing MPS II.

Conclusions: PPRCA is an uncommon condition with an uncertain origin that continues to be a subject of debate. Our case represents an unusual association that points to a potential genetic origin; however, further studies are needed to understand this condition.

Purpose: To review the existing literature to evaluate the utility of insulin eye drops as a treatment for neurotrophic-related epithelial defects.

Methods: A comprehensive literature search of Medline, Embase, and Web of Science and additional manual searches were conducted using relevant keywords. All articles published from January 2005 to January 2024 were examined. Studies on the use of topical insulin drops in neurotrophic epithelial defects were included.

Results: A total of 16 articles were found relevant to be discussed in the review. All included patients had neurotrophic-related epithelial defects ranging from 3.8 mm² to 144 mm². After treatment with topical insulin, most of the epithelial defects showed a complete epithelialization. Various concentrations and types of insulin were used. The studies also varied in the type of vehicle used in the preparation of insulin drops. Two randomized controlled trials demonstrated that topical insulin drops were more effective than conventional treatment with artificial tears or autologous serum. All included studies, except for two, reported the absence of local or systemic side effects.

Conclusions: Topical insulin is a promising and effective (adjuvant) treatment for neurotrophic keratopathy. It facilitates the healing of neurotrophic epithelial defects and offers many advantages over the current treatment options; insulin is widely available and it is relatively inexpensive. Topical insulin drops do not affect systemic blood glucose levels and are well tolerated. However, further investigation is needed.

Purpose: To evaluate the prevalence of dry eye, meibomian gland dysfunction (MGD), and conjunctivochalasis in patients with obstructive sleep apnea (OSA).

Methods: We included 37 patients diagnosed with OSA according to polysomnography. The control group comprised 31 subjects. The study participants underwent a complete ophthalmic examination and ocular surface assessment. Meibography was done using infrared imaging. Furthermore, tear meniscus height was measured using anterior segment optical coherence tomography.

Results: The mean age of the OSA and control groups were 50.3 ± 9.0 and 50.3 ± 8.0, respectively (P = 0.77). The mean scale for meibomian gland expression, meibomian gland plugging, and lid margin telangiectasia was similar in both groups. The meiboscores of the upper and lower eyelids were similar in both groups (upper meiboscores of 0.67 ± 0.48 and 0.37 ± 0.49 in OSA and control group, P = 0.180 and lower meiboscores of were 0.47 ± 0.57 and 0.22 ± 0.42 in OSA and control group, P = 0.179). The mean tear break-up time (TBUT) was significantly lower in the OSA group (8.17 ± 3.70 compared to 11.47 ± 4.52, P < 0.001). Upper and lower tear meniscus height were 186.14 ± 40.11 μm and 199.59 ± 37.22 μm and 237.25 ± 82.86 μm and 218.59 ± 68.8 μm in OSA and control group, respectively (P = 0.221, P = 0.166). The mean conjunctivochalasis grading score was 0.92 ± 0.72 and 0.81 ± 0.65 in the OSA and control groups, respectively (P = 0.143).

Conclusions: Despite decreased TBUT in patients with OSA, other dry eye parameters are not altered in these patients. Moreover, the frequency of MGD and conjunctivochalasis is not higher in OSA patients.

Purpose: To study the outcomes and complications of Nd: YAG laser capsulotomy in patients with uveitis.

Methods: This study retrospectively evaluated outcomes of Nd: YAG laser capsulotomy in 260 eyes of 260 patients with uveitis. The main indications for performing capsulotomy were a visually significant posterior capsule opacification (PCO) and inability to visualize the posterior segment. The presence of 5 or <5 cells per high-power field in the anterior chamber for a minimum period of 3 months was a prerequisite for capsulotomy.

Results: The mean age of patients was 52.8 ± 11.3 (range, 38-75 years). The incidence of PCO in the study was 22.4%. The mean follow-up was 21.5 ± 11.3 months postcapsulotomy. The mean best-corrected visual acuity (BCVA) improved in 161 (62%) eyes after capsulotomy. The BCVA remained stable in 50 (19.3%) eyes due to preexisting ocular pathology involving the macular area. There was worsening of BCVA in 49 (18.8%) eyes. The main causes of worsening of BCVA were sustained intraocular pressure (IOP) elevation (n = 13%), cystoid macular edema (CME) (n = 8.5%), and retinal detachment (RD) (n = 2.7%), respectively. Ninety-one percent (n = 20) of patients with CME had exaggerated postlaser inflammation and recurrent uveitis. The presence of posterior vitreous detachment (PVD) and higher laser energy levels were significant risk factors for RD.

Conclusions: Nd: YAG laser capsulotomy in patients with uveitis may be associated with complications. Inflammation and IOP should be well controlled before initiating laser capsulotomy. Capsulotomy should be performed with caution in patients with preexisting PVD.

Purpose: To describe the first reported instance of an acute chorioretinal inflammatory response to cabozantinib.

Methods: Case report.

Results: A 54-year-old Asian male presented with blurred vision 2 weeks following the commencement of cabozantinib for metastatic renal cell carcinoma. Ophthalmic examination revealed bilateral exudative retinal detachments and choroiditis in a pattern similar to Vogt-Koyanagi-Harada disease. Further investigations revealed latent tuberculosis (TB), and management of this ocular adverse event was with cabozantinib cessation, high-dose oral prednisone, single-agent anti-TB therapy, and methotrexate. Return of visual function and ocular anatomy occurred within 1 month.

Conclusions: Modern pharmacotherapy for metastatic cancer may increase survival, but a range of ocular and systemic adverse events are frequently seen. Screening and early intervention can mitigate adverse events and treatment burden, while maximizing benefits for this disadvantaged patient group.

Purpose: To develop an artificial intelligence (AI) approach for differentiating between normal cornea, subclinical, and keratoconus (KC) using tomographic maps from Pentacam (Oculus) and corneal biomechanics from Corvis ST (Oculus).

Methods: A total of 1,668 tomographic (769 patients) and 611 biomechanical (307 patients) images from the Chula Refractive Surgery Center, King Chulalongkorn Memorial Hospital were included. The sample size was divided into the Pentacam and combined Pentacam-Corvis groups. Different convolutional neural network approaches were used to enhance the KC and subclinical KC detection performance.

Results: AI model 1, which obtained refractive maps from Pentacam, achieved an area under the receiver operating characteristic curve (AUC) of 0.938 and accuracy of 0.947 (sensitivity, 90.8% and specificity, 96.9%). AI model 2, which added dynamic corneal response and the Vinciguerra screening report from Corvis ST to AI Model 1, achieved an AUC of 0.985 and accuracy of 0.956 (sensitivity, 93.0% and specificity, 94.3%). AI model 3, which added the corneal biomechanical index to AI Model 2, reached an AUC of 0.991 and accuracy of 0.956 (sensitivity, 93.0% and specificity, 94.3%).

Conclusions: Our study showed that AI models using either anterior corneal curvature alone or combined with corneal biomechanics could help classify normal and keratoconic corneas, which would make diagnosis more accurate and would be helpful in decision-making for the treatment.

Purpose: To evaluate and compare optical coherence tomography angiography (OCTA) retinal vasculature measurements in healthy, glaucoma suspect (GS), and glaucoma patients.

Methods: One hundred fourteen eyes with good quality OCTA pictures were included from 38 healthy, 38 GS, 38 and primary open-angle glaucoma (POAG) participants. The information on retinal vasculature was summarized as a vessel density map and as vessel density (%), which is the fraction of the flowing vessel area over the total area examined. The superior, inferior, nasal, and temporal quadrants, as well as whole vessel density (wVD) and peripapillary vessel density (ppVD) data taken from the retinal nerve fiber layer, were studied. Global indices of the visual field were correlated with vessel density measurement.

Results: Mean vessel density was significantly lower in POAG eyes compared with GSs and healthy eyes (wVD) 45.34% ± 6.64%, 50.06% ± 1.97% and 53.06% ± 2.12%, respectively (P < 0.001), and ppVD 47.42% ± 7.73%, 47.42% ± 7.73% and 56.074% ± 2.71%, respectively (P < 0.001). A linear relationship between vessel density (wVD and ppVD) and global indices of the visual field (mean deviation [MD] and pattern standard deviation [PSD]) shows a significant (P < 0.001) relation. R ² is 0.35, 0.36, 0.36, and 0.33 for MD and wVD, PSD and wVD, PSD and ppVD, and MD and ppVD, respectively.

Conclusions: For distinguishing between healthy and glaucoma eyes, OCTA vessel density demonstrated near similar diagnostic accuracy to visual field tests. These findings imply that OCTA measurements reflect damage to tissues important in the pathogenesis of POAG.